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ABSTRACT
Introduction Immune activation has been reported in
the mucosa of IBS patients with diarrhoea (IBS-D), and
some small studies have suggested that mesalazine may
reduce symptoms. We performed a double-blind,
randomised placebo-controlled trial of 2 g mesalazine
twice daily versus placebo for 3 months in patients with
Rome III criteria IBS-D. Primary outcome was daily
average stool frequency during weeks 11–12; secondary
outcomes were abdominal pain, stool consistency,
urgency and satisfactory relief of IBS symptoms.
Methods Participants were randomised after a 2-week
baseline stool diary. All participants completed a
12-week stool diary and at the end of each week
recorded the presence of ‘satisfactory relief of IBS
symptoms’.
Results 136 patients with IBS-D (82 women, 54 men)
were randomised, 10 patients withdrew from each
group. Analysis by intention to treat showed the daily
average stool frequency during weeks 11 and 12 were
mean (SD), 2.8 (1.2) in mesalazine and 2.7 (1.9) in
the placebo group with no signiﬁcant group difference,
(95% CI) 0.1 (−0.33 to 0.53), p=0.66. Mesalazine did
not improve abdominal pain, stool consistency nor
percentage with satisfactory relief compared with
placebo during the last two-weeks follow-up.
Conclusions This study does not support any clinically
meaningful beneﬁt or harm of mesalazine compared
with placebo in unselected patients with IBS-D. More
precise subtyping based on underlying disease
mechanisms is needed to allow more effective targeting
of treatment in IBS.
Trial registration number NCT01316718.
INTRODUCTION, BACKGROUND AND
OBJECTIVES
IBS is a heterogeneous condition seen commonly in
both primary and secondary care in the UK, where
it accounts for 3%1 and 40% of all consultations
respectively,2 a process that consumes considerable
medical resources. This chronic condition also
impacts on patients’ quality of life and their per-
formance at work and home.3 4 The diarrhoea
subtype particularly impairs quality of life by limit-
ing patients’ diet and the ability to travel or eat
out.5 Around two-thirds of patients with IBS show
anxiety or depression and multiple somatic
symptoms,6 but how much is cause and how much
is effect of the distressing symptoms remains
unclear and likely varies from case to case. IBS
with diarrhoea (IBS-D) may develop after inﬂam-
mation due to bacterial gastroenteritis (postinfec-
tious IBS (PI-IBS))7 in whom the immune response
can be prolonged.8 Recent studies have also shown
‘immune activation’ in the mucosa of patients with
IBS-D without an infectious origin. Increased
numbers of mast cells and release of mast cell med-
iators such as mast cell tryptase, serotonin and his-
tamine have been reported in some9–11 but not all
series.12 Other immune cells such as T lymphocytes
and serotonin (5-hydroxytryptamine (5-HT)) con-
taining enterochromafﬁn cells have been reported
as increased in PI-IBS.13 Numerous recent studies
have suggested impaired mucosal barrier in IBS,14
which by allowing access of luminal bacterial pro-
ducts to the mucosal immunocytes might cause
immune activation.15 These studies suggested that
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Signiﬁcance of this study
What is already known on this subject?
▸ Treatment for IBS with diarrhoea (IBS-D) is
limited and normally based on symptom
control.
▸ Ongoing ‘immune activation’ in the gut mucosa
of patients with IBS-D.
▸ Mesalazine may be beneﬁcial for the treatment
of IBS-D symptoms.
What are the new ﬁndings?
▸ Mesalazine 4 g/day was no better than placebo
in relieving symptoms of abdominal discomfort
or disturbed bowel habit.
▸ Mesalazine did not reduce mast cell percentage
area stained.
▸ Raised stool calprotectin level was associated
with less psychological distress implying a more
gut-centred abnormality.
How might it impact on clinical practice in
the foreseeable future?
▸ A subgroup of patients with postinfectious IBS
may beneﬁt from mesalazine.
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an anti-inﬂammatory treatment might be beneﬁcial, an idea that
has been supported by some small pilot studies that appeared to
show improvement in abdominal pain, stool frequency and con-
sistency, especially in patients with PI-IBS.16 17 One study
showed a reduction of mast cells following treatment of mesala-
zine in 10 unselected patients with IBS,18 but like the other
studies, it was too small to be sure of its signiﬁcance. Our aim
was therefore to assess the effect of mesalazine as a treatment
for IBS-D and to also assess its impact on mast cell numbers and
mediator release in an attempt to predict treatment response.
METHODS
Trial design
This was a multicentre, two-arm, parallel group, double-blind,
randomised placebo-controlled trial comparing mesalazine with
placebo in patients with IBS-D. Eligible participants were rando-
mised to receive either mesalazine or placebo 2 g once a day for
a week, and if they tolerated the dose, it was increased to 2 g
twice a day for 11 weeks. There were four visits altogether
(weeks −2, 0, 6 and 12) and telephone visits in between (weeks
1, 3 and 9) to ensure tolerance and compliance with medication
(ﬁgure 1). Participants were required to complete weekly stool
diaries for 12 weeks. We collected stool and sigmoid biopsy
samples before and at the end of trial (EOT) to look for biomar-
kers, but for practical reasons this was only performed on those
patients recruited in Nottingham. The trial was registered on clin-
icaltrials.gov (identiﬁer NCT01316718) and European Union
clinical trials register with EudraCT number 2010-018340-14.
Initial recruitment into this trial was slow, and it was felt that the
eligibility criteria for IBS-D were too demanding. We therefore
modiﬁed the eligibility criteria for IBS-D (see section
‘Participants’) following registration with the clinicaltrials.gov to
reﬂect the fact that, as others have found, the bowel habit of
patients with IBS-D is less abnormal than patients’ recall
suggests.19
Randomisation and blinding
This was a double-blind parallel group study. The participant,
supervising doctor and/or study nurse were unaware of the
treatment allocation. The randomisation was based on a
computer-generated pseudo-random code using random
permuted blocks of randomly varying size, created by the
Nottingham Clinical Trials Unit (NCTU) in accordance with
their standard operating procedure and held on a secure server.
Allocation was stratiﬁed by the recruiting centre. The supervis-
ing doctor or study nurse obtained a randomisation reference
number for each participant by means of a remote, internet-
based randomisation system developed and maintained by
NCTU. The sequence and decode of treatment allocations were
concealed until all interventions were assigned and recruitment,
data collection and all other trial-related assessments were com-
pleted and study ﬁles locked. The NCTU Data Manager and the
Nottingham University Hospitals Trust Trials pharmacy had
access to the treatment allocation. All data collected were
entered into a secured online database set up by NCTU.
A trial management group was set up to oversee the oper-
ational aspects of the trial. The group met regularly to review
progress of the trial and address any urgent issues. The Data
Monitoring and Ethics committee undertook the safety moni-
toring functions of the trial and provided recommendations to
the trial steering committee over the course of the trial. A trial
steering committee was set up to ensure the study was well
executed.
Sample size calculation
Our previous study on patients with IBS-D gave a mean stool
frequency of 3.1 (SD 2.0). Tuteja and colleagues reported mesa-
lazine decreasing stool frequency by 1.4 bowel movements per
day.20 Our study had 80% power to detect such an effect at the
1% two-sided α level.
Much smaller numbers were needed to assess the effect of
mesalazine on mast cell numbers and tryptase release.
Corinaldesi et al18 reported a 36% decrease in mast cell
numbers from mean 9.2 (SD 2.5), which requires just 16
patients in each group to show such a decrease with a power of
90% at the 5% α level. We therefore decided to assess the biop-
sies on patients recruited in Nottingham only in order to ensure
uniform processing.
We aimed to randomise at least 125 patients to allow for 20%
dropout rate, but owing to recruitment ongoing at multiple sites
and patient requests, we actually recruited 136.
Figure 1 Study design. This shows
the timeline for the study and the
12-week treatment period during
which participants were randomised to
receive either mesalazine or placebo.
bd, twice daily; EOT, end of trial; ,
telephone visits.
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Participants
Patients with IBS-D were recruited from gastroenterology clinics
at the Nottingham University Hospitals, seven other secondary
care hospitals in the UK and via the Trent Primary Care
Research Network from 1 April 2011 to 31 May 2013. The
patients were required to meet the modiﬁed Rome III criteria
for IBS-D,21 deﬁned as a stool frequency of ≥3/day for >2 days/
week and ≥25% of stools to be of type 5–7 and ≤25% type 1–2
according to the Bristol Stool Form Scale (BSFS),22 as assessed
from their screening stool diaries. The unmodiﬁed Rome III cri-
teria require ≥25% of stools to be of type 6–7, but we found
this excluded around one-third of otherwise typical patients
who met Rome III criteria based on recall, hence the modiﬁca-
tion. To exclude other causes of diarrhoea, we required normal
colonoscopy and colonic biopsies, normal full blood count,
serum calcium and albumin, C-reactive protein and negative
serological test for coeliac disease. Lactose intolerance was
tested by asking patients to consume 568 mL (1 pint) of milk
after an overnight fast and performing a lactose breath hydrogen
test if they developed pain or diarrhoeal symptoms within 3 h.
If the stools were watery and frequent, patients underwent a
7-day retention of selenium75-labelled homocholic acid taurine
test or a trial of cholestyramine to exclude bile acid malabsorp-
tion. If any of these tests were positive, patients were excluded
from the study. Most patients have continued to be followed up,
and no new diagnoses have emerged. Other inclusion criterion
was age 18–75 years. Exclusion criteria were prior history of
major abdominal surgery, liver or kidney impairment or chronic
ingestion of any anti-inﬂammatory drugs or medications that
could affect the gut motility. All childbearing female patients
tested negative on the pregnancy test during the randomisation
day and had to agree to adequate contraception during the trial.
Patients who were on long-term selective serotonin reuptake
inhibitors or tricyclic antidepressants were included if they were
on a stable dose for 3 months and willing to keep the dose
unaltered throughout the trial. During the screening period of
2 weeks, patients were only allowed a maximum of two doses
of 4 mg loperamide per week. Once randomised, patients were
allowed to take loperamide to control their symptoms as we
hypothesised that mesalazine would take at least six weeks to
exert its effect on the gut, assuming that it acts by altering the
immunocytes within the mucosa. However, during the last two
weeks of the trial when the bowel movement endpoints were
assessed, the patients were not allowed any loperamide or
antibiotics.
Investigational medical product
The mesalazine used for this study was a licensed slow release
granule formulation of 2 g (PENTASA, Ferring Pharmaceuticals)
and a matching placebo granule formulation (QPharma AS,
Sweden). In order to maintain blinding, active and placebo gran-
ules were packed in matching, unidentiﬁed, trial-speciﬁc foil
sachets (Ferring Pharmaceuticals). Newcastle Specials at
Newcastle-upon-Tyne Hospital National Health Service
Foundation Trust carried out ﬁnal labelling and release of
blinded trial treatment packs. All sites involved had appropriate
licences in place.
Data collection
Baseline demographics were collected at visit 1 (screening visit)
including age, gender and ethnicity. Data for Hospital and
Depression Scale23 (HADS) and score from the Patient Healthy
Questionnaire 1524 (PHQ15) were collected at visit 2, after
randomisation and at ﬁnal visit 4 (EOT). We used a 7-day
weekly stool diary throughout the trial to provide information
on the stool form based on BSFS, abdominal pain severity,
urgency of defecation and abdominal bloating. The latter three
symptoms were scored between 0 (no symptom) and 10
(extremely severe).
Compliance
Compliance was deﬁned a priori as taking ≥75% of the medica-
tion throughout the 12 weeks. Each patient was given two
boxes of medication during the 12-week study, each box con-
taining 100 sachets. The amount of medication taken was calcu-
lated from the number of medication sachets returned at EOT.
Compliance with medication and baseline characteristics of
compliers (deﬁned as taking >75% of the medication through-
out the 12 weeks) and non-compliers were similar in both
groups (see online supplementary table S5).
Outcomes
Clinical outcomes
The primary clinical outcome was stool frequency in the last
two weeks of trial follow-up (weeks 11 and 12). Secondary out-
comes were abdominal pain, urgency and stool consistency.
These were averaged over the last two weeks of the trial
follow-up. At the end of each week, patients were asked, “Have
you had satisfactory relief of your IBS symptoms this week?”.
Satisfactory relief of IBS symptoms at EOT was deﬁned as
answers to ‘yes’ on both weeks 11 and 12 of stool diary.
Information provided for <10 of 14 days of stool diary was
recorded as missing. All completed an assessment of anxiety and
depression (Hospital Anxiety and Depression Scale), and mul-
tiple somatic symptoms were recorded using the Patient Health
Questionnaire-12 Somatic Symptom Scale (PHQ12-SS).6
Mechanistic outcomes
The primary mechanistic endpoint was to assess the mast cell
numbers from the percentage area stained at week 12. The sec-
ondary endpoint was to assess mast cell activation in biopsy
supernatants and to relate these to symptoms. Mast cell activa-
tion was deﬁned as elevation of any mediator component
including mast cell tryptase, chymase, carboxypeptidase A3 and/
or histamine.
Stool samples and sigmoid colon biopsies
These were collected at week 0 and EOT from patients recruited
in Nottingham. Stools collected were analysed for calprotectin.
A commercially available calprotectin ELISA kit (Buhlmann,
Schönenbuch, Switzerland) was used for extraction and quantiﬁ-
cation of stool calprotectin. Normal range for stool calprotec-
tion is deﬁned as <50 μg/g.
Sigmoid biopsies were collected for immunohistochemistry
for mast cell tryptase, CD3, CD68 and 5-HT. Tissues were pro-
cessed and stained in the histopathology laboratory in
Nottingham University Hospitals Trust, UK. While other cells
were individually counted per mm2 mast cell, numbers were
assessed from the percentage area stained in the area of interest
as this was felt to more accurately reﬂect mast cell activity by
including mast cells, which were degranulating and hence indis-
tinct. A further set of biopsies was maintained in culture, and
supernatants collected were assayed for mast cell tryptase,
chymase, carboxypeptidase A3 and histamine. The biopsy
tissues were incubated immediately in Hanks’ medium at 37°C,
5% CO2 for 30 min before storing at −80°C until assays for mast
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cell mediators were performed by the Immunopharmacology
Group at the University of Southampton.
See supplementary ﬁle for details of methods for immunohis-
tochemical staining for mast cell tryptase, CD3, CD68 and
5-HT staining and measurement of mast cell mediator release.
Statistical methods
Analysis and presentation of data was in accordance with
Consolidated Standards of Reporting Trials guidance, using
Stata V.13. Balance between the trial arms at baseline was exam-
ined using appropriate descriptive statistics.
The general approach for between-group comparisons was to
analyse participants according to allocation without imputation
of missing data. The primary data set comprised participants
with completed stool diary for at least 10 days out of 14. We
used a generalised linear mixed model to compare mesalazine
group and placebo group for the primary outcome, with adjust-
ment for the baseline value of the outcome, and study centre as
a random effect. Additionally, we adjusted for any variables
showing imbalance at baseline in secondary models. We com-
pared the characteristics of participants who did and did not
adhere to the study medication before estimating the treatment
effect if the medication was actually taken using complier
average causal effect (CACE) analysis. We investigated the effect
of missing primary outcome data using multiple imputation.
The secondary outcomes were assessed using similar models as
for primary outcome, or logistic or Poisson regression as appro-
priate dependent on outcome type.
We conducted a number of prespeciﬁed subgroup analyses for
each of the following three outcomes: (1) stool frequency
during weeks 11–12, (2) number of days with any stool consist-
ency scoring 6 or 7 during weeks 11–12 and (3) mean score of
worst pain for each day averaged over weeks 11 and 12. We
investigated whether there were any differences in
between-group effects according to the following baseline vari-
ables: (1) anxiety, (2) stool frequency, (3) abdominal pain and
(4) mast cell activation. These subgroup analyses were con-
ducted by including appropriate interaction terms in the regres-
sion models, and as the study was not powered on the basis of
detecting any such subgroup effects, these are considered
exploratory and would require conﬁrmation in future research.
The primary mechanistic hypothesis to be investigated was
that treatment with mesalazine reduces inﬂammation, which in
turn reduces clinical symptoms. The aim of this type of analysis
is to estimate how much of any observed treatment effect can be
attributed to a variable that is thought to be an intermediate on
the causal pathway, or mediator. After summarising inﬂamma-
tory markers at baseline and 11–12 weeks’ follow-up by trial
arm using appropriate descriptive statistics, we examined change
in these markers (stool calprotectin, mast cell tryptase, mast cell




A total of 221 patients were screened for this trial, of whom 85
were excluded from the study and 136 were randomised 1:1 to
receive either mesalazine or placebo (ﬁgure 2). The commonest
reasons for exclusion were (a) failure to meet the required sever-
ity of diarrhoea on the 2-week diary during the initial 2-week
screening period and (b) patients not able to commit their time
to the study due to the multiple visits to hospital. In total, 116
patients completed the study, of whom 115 (57 treatment
and 58 control) had primary outcome data available. One
patient from the placebo group did not complete the stool diary
at 11–12 weeks and was therefore excluded. The number of
days with stool diary entered at baseline and at EOTwas similar
(see online supplementary table S7). There were no differences
in baseline characteristics between patients who dropped out
(non-completer) and those who completed the study (com-
pleter) (see online supplementary table S2).
Baseline characteristics of randomised patients in both treat-
ment groups were similar at baseline (table 1). All except four
participants were of Caucasian ethnicity.
Clinical outcomes
Primary outcome
There was no evidence of any difference between Mesalazine
and placebo treatment in reduction of daily average stool fre-
quency. The daily average stool frequency at EOT (weeks 11
and 12) was similar between the two groups, with mean (SD) of
2.8 (1.2) in Mesalazine and 2.7 (1.9) in placebo groups, and
adjusted between-group difference (95% CI) of 0.1 (−0.33 to
0.53), p=0.66. Additional adjustments for variables (age,
abdominal pain score, number of days with urgency and
PHQ15 score) displaying imbalance at baseline did not materi-
ally change the results. Sensitive analysis using multiple imput-
ation of missing data did not show any difference in daily
average stool frequency between Mesalazine and placebo with
adjusted difference in mean frequency (95% CI) of 0.06 (−0.18
to 0.99), p=0.17.
Figure 2 Participant ﬂow in the study. ITT, intention to treat.
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Compliance
Analysis of the primary outcome using CACE approach showed
no difference between the two treatment arms with mean differ-
ence (95% CI) of 0.2 (−0.6 to 0.9).
Preplanned subgroup analysis of the primary outcome by
baseline daily average stool frequency suggested that mesalazine
may be more effective among patients with greater baseline
stool frequency (table 2). The adjusted interaction coefﬁcient
was −0.26, 95% CI −0.51 to −0.01, p=0.04. There was no evi-
dence of any subgroup effects according to baseline abdominal
pain (p=0.36) or baseline HADS (p=0.79).
Secondary endpoints
There was no evidence of any differences between the groups in
clinical symptoms such as abdominal pain severity, average stool
consistency and number of days with stool consistency type 6–7
(table 3). There was strong evidence that mesalazine treatment
increased the number of days with urgency by about 20%.
There was no effect on the HADS score and somatic symptom
score PHQ12-SS following treatment of mesalazine compared
with placebo (table 3).
Mechanistic outcomes
Primary endpoint
Initial baseline mast cell assessments were compared with 21
healthy controls in a study performed previously using an iden-
tical protocol25 and 49 patients with IBS-D in this study. Due to
patient withdrawals, there were 41 biopsy samples, before and
after treatment, available for analysis (22 mesalazine, 19
placebo). The baseline mast cell percentage area stained were
similar between patients with IBS-D and the healthy controls
giving a median (IQR) of 2.25 (1.86–2.73) vs 2.42 (2.09–3.39)
% (ﬁgure 3A). Following treatment with mesalazine, there was
no signiﬁcant change in mast cell percentage area stained com-
pared with placebo. The mean difference (SD) in mast cell per-
centage area stained following treatment with mesalazine was
0.09 (0.55) and with placebo was −0.19 (0.76) % (ﬁgure 3B).
Secondary endpoints
There was no correlation between mast cell percentage area
stained and clinical symptoms of average abdominal pain sever-
ity, bloating, urgency, average stool frequency and average stool
consistency. There was no signiﬁcant association between mast
cell percentage area stained in biopsy tissue and supernatant
levels of tryptase, chymase, carboxypeptidase A3 or histamine
(see online supplementary table S3).
Immune cells
There was no effect of either treatment on 5-HT containing
enterochromafﬁn and CD68 cell numbers. Surprisingly, there
was signiﬁcant increase in CD3 count in the mesalazine group at
EOT (ﬁgure 3C) with mean difference (SD) CD3 count of 140
(349) /m2 compared with placebo 33.1 (153) /m2.
Stool calprotectin
A subgroup of patients from the Nottingham site provided stool
samples for calprotectin analysis. A total of 55 stool samples
were collected at the randomisation visit and 53 samples at the
EOT visits. In total, 23 stool samples (before and after treat-
ment) were from the mesalazine group and 30 stool samples
(before and after treatment) were from the placebo group.
Baseline calprotectin level was 59 (19–113) μg/g. There was no
signiﬁcant change in stool calprotectin levels following treat-
ment with mesalazine. Mean differences (SD) were −12.2 (82.7)
for mesalazine and 0.1 (87.1) for placebo, p=0.99. There was a
weak inverse correlation between baseline calprotectin level
with total hospital and anxiety scores, Spearman r=−0.25,
p=0.07. We performed a post hoc explanatory analysis dividing
patients according to their baseline calprotectin levels into two
groups. Group A (n=14) had calprotectin levels >100 μg/g, and
group B (n=41) had calprotectin levels ≤100 μg/g. The total
HAD score was signiﬁcantly lower in group A compared with
group B with median (IQR) of 7 (4–14) and 13 (7–18), respect-
ively, p=0.03 (see online supplementary ﬁgure S1).
Postinfectious IBS
Thirteen patients with IBS-D from the study fulﬁlled the criteria
for PI-IBS.13 The mean stool frequency for PI-IBS and the
remaining patients with IBS-D were similar, giving a mean (SD)
of 4.25 (2.35) and 3.59 (1.70), respectively, p=0.48. Eight were
on mesalazine treatment and ﬁve on placebo. Their baseline
characteristics were similar (see online supplementary table S4).
Following treatment with mesalazine but not placebo, there
seemed to be signiﬁcant improvement in average abdominal
pain severity, average urgency score and average daily stool con-
sistency (see ﬁgure 4 and online supplementary ﬁgure S2).
Adverse events
The most frequently occurring side effect was exacerbation of
IBS symptoms, mostly worsening abdominal pain or diarrhoea.
Two (3%) from mesalazine and three (5%) from placebo group
complained of this and were withdrawn from the study. Other
Table 2 Subgroup analysis based on baseline daily average stool
frequency
Mesalazine (N=57) Placebo (N=58)
Daily mean stool frequency at 11–12 weeks by baseline frequency, mean (SD)
Baseline frequency ≤2.4 1.7 (0.4) 1.6 (0.5)
Baseline frequency >2.4 and ≤3.4 2.2 (0.5) 2.2 (1.1)
Baseline frequency >3.4 ≤4.6 3.1 (1.3) 2.7 (0.9)
Baseline frequency >4.6 4.1 (1.1) 4.7 (2.9)
Table 1 Baseline characteristics of randomised patients
Characteristic Mesalazine (N=68) Placebo (N=68)
Age at enrolment: mean (SD) 42.6 (15.2) 47.1 (13.5)
Gender N (%) Male 26 (38.2%) Male 28 (41.2%)
Female 42 (61.8%) Female 40 (58.8%)
Daily average stool frequency
Mean (SD)
3.6 (1.6) 3.6 (1.8)
Daily mean abdominal pain score
Mean (SD)
4.1 (2.2) 3.6 (2.0)
Number of days with urgency
Median (IQR)
13 (10,14) 12 (9,14)
Stool consistency
Mean (SD)
5.4 (0.7) 5.6 (1.0)
Hospital anxiety and depression score
Anxiety score
Mean (SD)
9.1 (4.5) 8.6 (4.3)
Depression score
Mean (SD)
5.6 (4.2) 5.0 (3.3)
PHQ12-SS score
Mean (SD)
7.8 (4.5) 8.2 (5.2)
PHQ12-SS, Patient Health Questionnaire-12 Somatic Symptom Scale.
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less frequent side effects are listed in online supplementary table
S6. One patient was pregnant in the middle of trial period,
although she had a negative pregnancy test at the start of the
trial. She was withdrawn from study with no adverse conse-
quence to herself or her newborn.26 One patient from the mesa-
lazine group was found to have breast cancer, and she was
withdrawn from the study as her IBS symptoms and stool diary
would be very difﬁcult to interpret. All participants who devel-
oped these adverse events were withdrawn from the study, and
their symptoms settled on follow-up.
DISCUSSION
Our study is one of the largest trials so far looking at the treat-
ment of mesalazine in patients with IBS-D following best prac-
tice to ensure that both investigators and patients were blinded
to the study and that data analysis was carried out by independ-
ent statisticians. We analysed the effect of mesalazine only after
12-weeks treatment as we felt that mesalazine was a disease-
modifying treatment rather than symptomatic treatment and
early reports suggested beneﬁt was most obvious after
2–3 months.27
Our study showed that mesalazine did not improve bowel fre-
quency after 12-weeks treatment compared with placebo in
unselected patients with IBS-D. As with other studies in IBS, we
found a strong placebo effect on bowel symptoms and also on
the total Hospital Anxiety and Depression and Somatic scores
(PHQ12-SS), suggesting that patients felt better in general after
taking part in the trial. We found no evidence that the improve-
ment in HADS or PHQ12-SS correlated with changes in bowel
habit, suggesting these are independent features and not causally
related.
Despite lack of beneﬁt in unselected patients, we had a pre-
planned subgroup analysis of the primary outcome of stool fre-
quency in patients divided according to severity. This suggested
that a group of patients who had the greatest bowel frequency
did beneﬁt from mesalazine. Our clinical ﬁndings seem consist-
ent with another recent report.28 There was no signiﬁcant
improvement in other IBS symptoms such as abdominal pain,
bloating and stool consistency. There is strong evidence from
our study that mesalazine treatment increases the number of
days with urgency by about 20%. There have been previous
case studies reported of mesalazine worsening diarrhoea in
colitis.29 30 This may represent an allergic response to the drug
as we did ﬁnd an increase in T lymphocytes.
Raised mast cell numbers in the gut mucosa have been impli-
cated in all subtypes of IBS31 but mainly in IBS-D. Mast cells




at 11–12 weeks (95% CI) p Value
Average abdominal pain score, mean (SD)
Placebo 2.2 (2.1) – –
Mesalazine 2.8 (2.1) – –
Mesalazine vs placebo – 0.07 (−0.54 to 0.68) 0.83
Number of days with urgency, median (IQR)
Placebo 8 (1–13) – –
Mesalazine 11 (5–14) – –
Mesalazine vs placebo – 1.22 (1.07 to 1.39)* 0.003
Average stool consistency, mean (SD)
Placebo 4.7 (1.1) – –
Mesalazine 4.7 (1.0) – –
Mesalazine vs placebo – 0.13 (−0.21 to 0.48) 0.45
Number of days with consistency score 6 or 7, median (IQR)
Placebo 6 (2–9) – –
Mesalazine 7 (2–11) – –
Mesalazine vs placebo – 1.09 (0.95 to 1.27) 0.21
Number of people with satisfactory relief of IBS symptoms, n (%)
Placebo 24 (40.7%) – –
Mesalazine 25 (43.9%) – –
Mesalazine vs placebo – 1.13 (0.51 to 2.47)† 0.76
Mean HADS anxiety score
Placebo 6.9 (3.6) – –
Mesalazine 7.5 (5.0) – –
Mesalazine vs placebo – 0.67 (−0.38 to 1.72) 0.21
Mean HADS depression score
Placebo 3.7 (3.2) – –
Mesalazine 4.7 (5.1) – –
Mesalazine vs placebo – 0.49 (−0.41 to 1.39) 0.29
Mean PHQ12-SS score (mean(SD))
Placebo 5.7 (3.9) – –
Mesalazine 6.2 (4.4) – –
Mesalazine vs placebo – 0.49 (−0.76 to 1.74) 0.45
*Incident rate ratio.
†OR.
EOT, end of trial; HADS, Hospital and Depression Scale; PHQ12-SS, Patient Health Questionnaire-12 Somatic Symptom Scale.
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contain many mediators including histamine, serotonin and pro-
teases such as tryptase.10 Recently, there has been an interest in
tryptase from both mast cells and endogenous pancreatic secre-
tion32 as it has been shown to activate proteinase-activated recep-
tor 2, which is found on afferent nerves and can lead to increased
sensitivity of bowel distension.33 In our study, the mast cell per-
centage area stained in patients with IBS-D was not elevated com-
pared with those in our previously studied healthy subjects. We
were not able to conﬁrm the gender difference in mast cell count
of patients with IBS-D previously described by others,34 nor did
we ﬁnd any gender effect on other immune cells such as CD3,
CD68 and 5-HTcontaining enterochromafﬁn cells.
Similarly, the supernatant tryptase levels in patients with IBS-D
were not signiﬁcantly elevated compared with healthy control.
Median (IQR) tryptase levels for IBS-D versus healthy control
were 4.3 (1.8–8.9) and 6.7 (3.8–11.4) ng/mL, p=0.07.
Surprisingly, supernatant histamine levels in our study were
lower in patients with IBS-D compared with healthy control,
being mean (SD), 0.7 (0.6) and 1.1 (0.8) ng/mL, respectively,
p=0.02. There was no correlation between baseline tryptase/his-
tamine/chymase/CPA3 with clinical symptoms. Supernatant
levels of tryptase and histamine were not altered following treat-
ment of mesalazine. We found no apparent association between
mast cell percentage area stained and supernatant levels of the
mast cell mediators examined whether those released by all mast
cells (tryptase, histamine) or restricted to a subpopulation
(chymase, carboxypeptidase A3). This suggests that the overall
degree of mediator release from colonic mast cells is independent
of mast cell numbers and factors other than mere numbers deter-
mine mediator release. We were not able to conﬁrm either
increased mast cell numbers nor increased mast cell tryptase
release from biopsies as some9 10 but not all12 investigators have
found. Our study provides no support for the previous sugges-
tion that mesalazine can reduce mast cell numbers.18
Stool collected in Nottingham was used to obtain calprotectin
level at baseline and EOT. Although the normal calprotectin
recommended by the commercial laboratory was <50 μg/g, there
is still an uncertainty with patients who have borderline results
(50–150 μg/g) as most of them do not have inﬂammatory bowel
disease.35 In this study, there were 28 patients with IBS-D who
have calprotectin levels >50 μg/g (median (IQR)=105.5 (73.5–
173.1)). On repeated testing (placebo group n=16), approxi-
mately 44% of the calprotectin levels had normalised after
12 weeks of placebo treatment, a feature others have noted in a
series of patients with IBS with intermediate calprotectin levels
(50–100 μg/g) subjected to repeated testing.35 For all patients
who were recruited into the study, we have excluded organic dis-
eases such as inﬂammatory bowel disease in gastroenterology
clinics using standard tests like normal haematology, biochemical
Figure 3 (A) Baseline mast cell percentage area stained in patients with IBS with diarrhoea (IBS-D) and healthy controls (HV); (B) mast cell
percentage area stained before and after mesalazine or placebo groups; (C) CD3-positive cells before and after treatment with mesalazine or placebo.
Figure 4 Improvement of abdominal pain severity following
treatment of mesalazine in patients with post-infectious IBS.
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and ileocolonoscopy prior to them entering the study.
Furthermore, patients have had continued follow-up as outpati-
ents and no new diagnoses have emerged. Others have also
reported up to a quarter of patients with IBS have marginally ele-
vated calprotectin though the origin of this is unclear.36 37
Interestingly, the subgroup of patients (group A) who had raised
calprotectin level (>100 μg/g) have signiﬁcantly less psycho-
logical distress than the group with stool calprotectin level
≤100 μg/g (group B). We speculate that in subgroup A symptoms
are secondary to occult local gut inﬂammation while subgroup
B’s symptoms are driven primarily by distress, which causes gut
symptoms secondarily. Unfortunately, numbers were too small to
answer the question of whether subgroup A responded better to
mesalazine. Stool calprotectin could therefore be used as a
screening tool to allow more detailed studies of the mucosa in
IBS-D in the future.
One uncontrolled study has suggested that mesalazine might
be effective in treating patients with PI-IBS,16 but the only ran-
domised controlled trial of mesalazine in this condition was
negative, though possibly underpowered.17 In our post hoc ana-
lysis, a small subgroup fulﬁlling criteria for PI-IBS appeared to
beneﬁt from mesalazine, but our study was also underpowered.
Interestingly, the study of the outbreak of enterohaemorrhagic
Escherichia coli O104:H4 infection in Germany suggests that
mesalazine treatment substantially reduced the incidence of
PI-IBS,38 which further supports this idea that a larger and more
adequately powered study speciﬁcally focused on PI-IBS would
be worthwhile.
Although mesalazine has been available to use for many
decades with good safety proﬁle, our adequately powered study
has showed it does not help the majority of patients with IBS-D.
The fact that certain subgroups might beneﬁt emphasises that
there is still a need for better phenotyping of this heterogeneous
group of patients when evaluating new treatments.
Limitations
Despite strict entry criteria, our population was still heteroge-
neous. In retrospect, we would have been better if we had strati-
ﬁed by postinfectious onset. We did consider this but felt that
this would make the trial very difﬁcult to recruit to. We could
overcome this in future studies by having a great many more
recruitment sites and screening around ﬁve times as many parti-
cipants, given that PI-IBS accounts for only around 20% of all
cases of IBS-D, but this would require more resources than we
had available to us. It is worth noting that there is an appre-
ciable loss to follow-up (15.5%) but not out of line with other
similar IBS studies. Dropouts are mostly likely due to failure of
treatment and so unlikely to account for our negative result.
Research recommendations
1. Our data suggest that it is unlikely that future trials of mesa-
lazine in unselected IBS would be fruitful.
2. If there is a subgroup that beneﬁt, it is likely to be those with
PI-IBS and a trial of such carefully selected patients would be
worthwhile, particularly those with more severe diarrhoea.
3. Future work on the role of mast cells needs to better charac-
terise the patients since the majority of unselected IBS do
not have elevated mast cell numbers. It may be that as others
have reported it is the number of activated mast cells that are
important33 and better markers of activation would be
useful rather than the current gold standard of electron
microscopy, which is expensive, time consuming and prone
to sampling error.
4. Finally, the release of mediators from biopsies does not link
well to symptoms or mast cell numbers. The dominant factor
for release is likely to be crushing and tissue injury by the
biopsy process that is not well standardised and may over-
whelm other factors that would be of more interest. We need
a better way of assessing in vivo activity of the mucosal cells.
CONCLUSIONS
This randomised placebo-controlled trial in 115 unselected
patients with IBS-D showed that mesalazine 4 g/day was no
better than placebo in relieving the symptoms of abdominal
pain or disturbed bowel habit. However, contrary to the previ-
ous small study (n=10), mesalazine did not reduce mast cell per-
centage area stained. A small subgroup with PI-IBS appeared to
beneﬁt, but this requires a larger adequately powered study to
conﬁrm this ﬁnding.
Further phenotyping of the heterogeneous group of patients
with IBS and diarrhoea is needed to allow better evaluation of
new treatments
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